FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2792510157> ?p ?o ?g. }

• W2792510157 endingPage "1027" @default.
• W2792510157 startingPage "1017" @default.
• W2792510157 abstract "See Moon and Bradbury (doi:10.1093/brain/awy067) for a scientific commentary on this article. Many hundreds of thousands of people around the world are living with the long-term consequences of spinal cord injury and they need effective new therapies. Laboratory research in experimental animals has identified a large number of potentially translatable interventions but transition to the clinic is not straightforward. Further evidence of efficacy in more clinically-relevant lesions is required to gain sufficient confidence to commence human clinical trials. Of the many therapeutic candidates currently available, intraspinally applied chondroitinase ABC has particularly well documented efficacy in experimental animals. In this study we measured the effects of this intervention in a double-blinded randomized controlled trial in a cohort of dogs with naturally-occurring severe chronic spinal cord injuries that model the condition in humans. First, we collected baseline data on a series of outcomes: forelimb-hindlimb coordination (the prespecified primary outcome measure), skin sensitivity along the back, somatosensory evoked and transcranial magnetic motor evoked potentials and cystometry in 60 dogs with thoracolumbar lesions. Dogs were then randomized 1:1 to receive intraspinal injections of heat-stabilized, lipid microtube-embedded chondroitinase ABC or sham injections consisting of needle puncture of the skin. Outcome data were measured at 1, 3 and 6 months after intervention; skin sensitivity was also measured 24 h after injection (or sham). Forelimb-hindlimb coordination was affected by neither time nor chondroitinase treatment alone but there was a significant interaction between these variables such that coordination between forelimb and hindlimb stepping improved during the 6-month follow-up period in the chondroitinase-treated animals by a mean of 23%, but did not change in controls. Three dogs (10%) in the chondroitinase group also recovered the ability to ambulate without assistance. Sensitivity of the dorsal skin increased at 24 h after intervention in both groups but subsequently decreased to normal levels. Cystometry identified a non-significant improvement of bladder compliance at 1 month in the chondroitinase-injected dogs but this did not persist. There were no overall differences between groups in detection of sensory evoked potentials. Our results strongly support a beneficial effect of intraspinal injection of chondroitinase ABC on spinal cord function in this highly clinically-relevant model of chronic severe spinal cord injury. There was no evidence of long-term adverse effects associated with this intervention. We therefore conclude that this study provides strong evidence in support of initiation of clinical trials of chondroitinase ABC in humans with chronic spinal cord injury." @default.
• W2792510157 created "2018-03-29" @default.
• W2792510157 creator A5046943484 @default.
• W2792510157 creator A5072608448 @default.
• W2792510157 creator A5073690914 @default.
• W2792510157 creator A5089098581 @default.
• W2792510157 creator A5091611092 @default.
• W2792510157 date "2018-02-09" @default.
• W2792510157 modified "2023-10-17" @default.
• W2792510157 title "Therapeutic efficacy of microtube-embedded chondroitinase ABC in a canine clinical model of spinal cord injury" @default.
• W2792510157 cites W1963729509 @default.
• W2792510157 cites W1966007526 @default.
• W2792510157 cites W1966602829 @default.
• W2792510157 cites W1967109943 @default.
• W2792510157 cites W1974080327 @default.
• W2792510157 cites W1983891257 @default.
• W2792510157 cites W1985297297 @default.
• W2792510157 cites W1989158501 @default.
• W2792510157 cites W1989714645 @default.
• W2792510157 cites W1992292158 @default.
• W2792510157 cites W1995414607 @default.
• W2792510157 cites W1997721049 @default.
• W2792510157 cites W1998483724 @default.
• W2792510157 cites W2000033491 @default.
• W2792510157 cites W2002938162 @default.
• W2792510157 cites W2009005936 @default.
• W2792510157 cites W2012928251 @default.
• W2792510157 cites W2029320821 @default.
• W2792510157 cites W2033014977 @default.
• W2792510157 cites W2041592999 @default.
• W2792510157 cites W2042635405 @default.
• W2792510157 cites W2044381469 @default.
• W2792510157 cites W2050806750 @default.
• W2792510157 cites W2059640074 @default.
• W2792510157 cites W2065157474 @default.
• W2792510157 cites W2076782564 @default.
• W2792510157 cites W2084275244 @default.
• W2792510157 cites W2099359509 @default.
• W2792510157 cites W2100075263 @default.
• W2792510157 cites W2100615567 @default.
• W2792510157 cites W2103977342 @default.
• W2792510157 cites W2118374901 @default.
• W2792510157 cites W2118969721 @default.
• W2792510157 cites W2120990276 @default.
• W2792510157 cites W2142958905 @default.
• W2792510157 cites W2167208176 @default.
• W2792510157 cites W2413947359 @default.
• W2792510157 cites W2590303026 @default.
• W2792510157 cites W2591533639 @default.
• W2792510157 doi "https://doi.org/10.1093/brain/awy007" @default.
• W2792510157 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29444239" @default.
• W2792510157 hasPublicationYear "2018" @default.
• W2792510157 type Work @default.
• W2792510157 sameAs 2792510157 @default.
• W2792510157 citedByCount "53" @default.
• W2792510157 countsByYear W27925101572018 @default.
• W2792510157 countsByYear W27925101572019 @default.
• W2792510157 countsByYear W27925101572020 @default.
• W2792510157 countsByYear W27925101572021 @default.
• W2792510157 countsByYear W27925101572022 @default.
• W2792510157 countsByYear W27925101572023 @default.
• W2792510157 crossrefType "journal-article" @default.
• W2792510157 hasAuthorship W2792510157A5046943484 @default.
• W2792510157 hasAuthorship W2792510157A5072608448 @default.
• W2792510157 hasAuthorship W2792510157A5073690914 @default.
• W2792510157 hasAuthorship W2792510157A5089098581 @default.
• W2792510157 hasAuthorship W2792510157A5091611092 @default.
• W2792510157 hasBestOaLocation W27925101571 @default.
• W2792510157 hasConcept C105702510 @default.
• W2792510157 hasConcept C118552586 @default.
• W2792510157 hasConcept C126322002 @default.
• W2792510157 hasConcept C141071460 @default.
• W2792510157 hasConcept C168563851 @default.
• W2792510157 hasConcept C2778334475 @default.
• W2792510157 hasConcept C2778646069 @default.
• W2792510157 hasConcept C2780775167 @default.
• W2792510157 hasConcept C42219234 @default.
• W2792510157 hasConcept C51738704 @default.
• W2792510157 hasConcept C535046627 @default.
• W2792510157 hasConcept C71924100 @default.
• W2792510157 hasConcept C99508421 @default.
• W2792510157 hasConceptScore W2792510157C105702510 @default.
• W2792510157 hasConceptScore W2792510157C118552586 @default.
• W2792510157 hasConceptScore W2792510157C126322002 @default.
• W2792510157 hasConceptScore W2792510157C141071460 @default.
• W2792510157 hasConceptScore W2792510157C168563851 @default.
• W2792510157 hasConceptScore W2792510157C2778334475 @default.
• W2792510157 hasConceptScore W2792510157C2778646069 @default.
• W2792510157 hasConceptScore W2792510157C2780775167 @default.
• W2792510157 hasConceptScore W2792510157C42219234 @default.
• W2792510157 hasConceptScore W2792510157C51738704 @default.
• W2792510157 hasConceptScore W2792510157C535046627 @default.
• W2792510157 hasConceptScore W2792510157C71924100 @default.
• W2792510157 hasConceptScore W2792510157C99508421 @default.
• W2792510157 hasFunder F4320320043 @default.
• W2792510157 hasIssue "4" @default.
• W2792510157 hasLocation W27925101571 @default.
• W2792510157 hasLocation W27925101572 @default.

• next